The hidden costs of limiting access: clinical and economic risks of Medicare’s future effective cellular, acellular and matrix-like products (CAMPs) Local Coverage Determination

The hidden costs of limiting access: clinical and economic risks of Medicare’s future effective cellular, acellular and matrix-like products (CAMPs) Local Coverage Determination
🚨Medicare policy decisions should be informed by data from actual patients.🚨
This article, hot off the presses, confirms that the CAMPs LCDs are poorly designed and that CMS should rethink its skin substitute policy based on real world data rather than limited RCTs. In fact “The proposed CAMPs LCD could negatively impact outcomes for Medicare beneficiaries who experience adverse outcomes when treatment is prematurely limited . . . .”